Production (Stage)
Arbutus Biopharma Corporation
ABUS
$3.22
$0.000.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.94% | 4.02% | -1.63% | -5.70% | -6.22% |
| Total Depreciation and Amortization | -4.91% | -1.71% | 3.99% | 8.52% | 4.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 189.63% | 74.21% | -2.32% | 45.04% | 17.64% |
| Change in Net Operating Assets | 160.50% | 84.48% | 93.13% | 85.97% | 50.89% |
| Cash from Operations | 24.36% | 24.54% | 16.12% | 11.71% | 6.42% |
| Capital Expenditure | 91.18% | 81.94% | 91.59% | 89.34% | -77.98% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 200.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -51.47% | -55.31% | -24.81% | 196.90% | 1,892.97% |
| Cash from Investing | -50.64% | -54.80% | -22.96% | 217.51% | 2,455.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -12.44% | 69.66% | 43.40% | 19.64% | -14.94% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -12.44% | 69.66% | 43.40% | 19.64% | -14.94% |
| Foreign Exchange rate Adjustments | -500.00% | -296.00% | -128.57% | 105.26% | 144.44% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -338.43% | 323.67% | 321.15% | 276.87% | 106.20% |